Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains notched in the prior session, after a weight-loss pill from chief rival Eli Lilly ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

The price target adjustment represents an approximately 11% upside potential for Novo Nordisk shares, according to HSBC’s analysis. HSBC cited increased market share estimates for oral semaglutide as ...

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lilly 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.